NCT07179081View on ClinicalTrials.gov

A Study of AL58805 in Patients With Advanced Tumors

PHASE1RecruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

December 20, 2020

Primary Completion Date

January 26, 2026

Study Completion Date

January 26, 2026

Conditions
Advanced Tumors
Interventions
DRUG

AL58805

Oral,Multiple administrations, once or twice daily（20mg 、40mg QD; 20mg 、30mg、40mg、50mg、60mg BID；）

Trial Locations (1)

410013

RECRUITING

Hunan Cancer Hospital, Changsha

Sponsors
All Listed Sponsors
lead

Advenchen Laboratories Nanjing Ltd.

INDUSTRY